Literature DB >> 21189351

Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.

Charlotte Charpentier1, Bénédicte Roquebert, Olivier Delelis, Lucile Larrouy, Sophie Matheron, Roland Tubiana, Marina Karmochkine, Xavier Duval, Geneviève Chêne, Alexandre Storto, Gilles Collin, Antoine Bénard, Florence Damond, Jean-François Mouscadet, Françoise Brun-Vézinet, Diane Descamps.   

Abstract

We studied seven heavily pretreated HIV-2-infected patients exhibiting a virological failure while receiving a salvage raltegravir-containing regimen. At the time of virological failure, different resistance genetic pathways were observed: T97A-Y143C, Q148K, Q148R, G140S-Q148R, E92Q-Y143R-N155H, and T97A-N155H. Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21189351      PMCID： PMC3067093          DOI： 10.1128/AAC.00942-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast.

Authors:  D Pieniazek; D Ellenberger; L M Janini; A C Ramos; J Nkengasong; M Sassan-Morokro; D J Hu; I M Coulibally; E Ekpini; C Bandea; A Tanuri; A E Greenberg; S Z Wiktor; M A Rayfield
Journal:  AIDS Res Hum Retroviruses       Date:  1999-04-10       Impact factor: 2.205

2.  Raltegravir treatment response in an HIV-2 infected patient: a case report.

Authors:  Nigel Garrett; Li Xu; Erasmus Smit; Bridget Ferns; Saleh El-Gadi; Jane Anderson
Journal:  AIDS       Date:  2008-05-31       Impact factor: 4.177

3.  Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.

Authors:  Bénédicte Roquebert; Laurent Blum; Gilles Collin; Florence Damond; Gilles Peytavin; Juliette Leleu; Sophie Matheron; Geneviève Chêne; Françoise Brun-Vézinet; Diane Descamps
Journal:  AIDS       Date:  2008-10-01       Impact factor: 4.177

4.  Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.

Authors:  Hiroyu Hatano; Harry Lampiris; Signe Fransen; Soumi Gupta; Wei Huang; Rebecca Hoh; Jeffrey N Martin; Jacob Lalezari; David Bangsberg; Christos Petropoulos; Steven G Deeks
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

Review 5.  HIV resistance to raltegravir.

Authors:  Francois Clavel
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

6.  Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.

Authors:  María Salgado; Carlos Toro; Ainhoa Simón; Carolina Garrido; Francisco Blanco; Vincent Soriano; Berta Rodés
Journal:  J Clin Virol       Date:  2009-07-22       Impact factor: 3.168

7.  Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology.

Authors:  F Gao; L Yue; D L Robertson; S C Hill; H Hui; R J Biggar; A E Neequaye; T M Whelan; D D Ho; G M Shaw
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

8.  Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

Authors:  Isabelle Malet; Olivier Delelis; Cathia Soulie; Marc Wirden; Luba Tchertanov; Philippe Mottaz; Gilles Peytavin; Christine Katlama; Jean-François Mouscadet; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  J Antimicrob Chemother       Date:  2009-02-16       Impact factor: 5.790

9.  Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.

Authors:  Max Lataillade; Jennifer Chiarella; Michael J Kozal
Journal:  Antivir Ther       Date:  2007

10.  HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

Authors:  B Roquebert; F Damond; G Collin; S Matheron; G Peytavin; A Bénard; P Campa; G Chêne; F Brun-Vézinet; D Descamps
Journal:  J Antimicrob Chemother       Date:  2008-08-20       Impact factor: 5.790
View more
  11 in total

1.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Sally S Leong; Kate M Parker; Mariah K Oakes; Papa Salif Sow; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

3.  Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.

Authors:  Said A Hassounah; Thibault Mesplède; Peter K Quashie; Maureen Oliveira; Paul A Sandstrom; Mark A Wainberg
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

4.  Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.

Authors:  Robert A Smith; Dana N Raugi; Nancy B Kiviat; Stephen E Hawes; James I Mullins; Papa S Sow; Geoffrey S Gottlieb
Journal:  AIDS       Date:  2011-11-28       Impact factor: 4.177

5.  Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.

Authors:  Robert A Smith; Vincent H Wu; Jennifer Song; Dana N Raugi; Khardiata Diallo Mbaye; Moussa Seydi; Geoffrey S Gottlieb
Journal:  J Infect Dis       Date:  2022-08-26       Impact factor: 7.759

6.  Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.

Authors:  Robert A Smith; Dana N Raugi; Charlotte Pan; Matthew Coyne; Alexandra Hernandez; Brad Church; Kara Parker; James I Mullins; Papa Salif Sow; Geoffrey S Gottlieb
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

7.  HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

Authors:  Geoffrey S Gottlieb; Robert A Smith; Ndeye Mery Dia Badiane; Selly Ba; Stephen E Hawes; Macoumba Toure; Alison K Starling; Fatou Traore; Fatima Sall; Stephen L Cherne; Joshua Stern; Kim G Wong; Paul Lu; Moon Kim; Dana N Raugi; Airin Lam; James I Mullins; Nancy B Kiviat
Journal:  PLoS One       Date:  2011-07-12       Impact factor: 3.240

8.  G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.

Authors:  Xiao-Ju Ni; Olivier Delelis; Charlotte Charpentier; Alexandre Storto; Gilles Collin; Florence Damond; Diane Descamps; Jean-François Mouscadet
Journal:  Retrovirology       Date:  2011-08-19       Impact factor: 4.602

9.  In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.

Authors:  Robert A Smith; Dana N Raugi; Charlotte Pan; Papa Salif Sow; Moussa Seydi; James I Mullins; Geoffrey S Gottlieb
Journal:  Retrovirology       Date:  2015-02-05       Impact factor: 4.602

10.  HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.

Authors:  Joana Cavaco-Silva; Ana Abecasis; Ana Cláudia Miranda; José Poças; Jorge Narciso; Maria João Águas; Fernando Maltez; Isabel Almeida; Isabel Germano; António Diniz; Maria de Fátima Gonçalves; Perpétua Gomes; Celso Cunha; Ricardo Jorge Camacho
Journal:  PLoS One       Date:  2014-03-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.